Omeros Corporation (NASDAQ:OMER) shares traded down 4.8% during mid-day trading on Tuesday . The stock traded as low as $10.90 and last traded at $10.95, with a volume of 219,060 shares. The stock had previously closed at $11.50.

Several research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $62.00 target price on shares of Omeros Corporation in a report on Tuesday, May 10th. WBB Securities reaffirmed a “buy” rating and issued a $75.00 target price on shares of Omeros Corporation in a report on Tuesday, June 14th. Maxim Group reaffirmed a “buy” rating on shares of Omeros Corporation in a report on Wednesday, April 20th. FBR & Co reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Omeros Corporation in a report on Wednesday, June 29th. Finally, Zacks Investment Research cut shares of Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $38.22.

The firm’s market capitalization is $418.74 million. The stock’s 50 day moving average is $11.12 and its 200 day moving average is $12.17.

Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.11. The business had revenue of $7.40 million for the quarter, compared to the consensus estimate of $8.79 million. Omeros Corporation’s quarterly revenue was up 1797.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.51) EPS. Equities research analysts predict that Omeros Corporation will post ($1.76) EPS for the current fiscal year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $9.94, for a total transaction of $158,046.00. Following the transaction, the vice president now directly owns 179,497 shares in the company, valued at approximately $1,784,200.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Several hedge funds have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors boosted its stake in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares in the last quarter. California State Teachers Retirement System boosted its stake in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 1,249 shares in the last quarter. Brown Advisory Inc. boosted its stake in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock worth $8,332,000 after buying an additional 163,306 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock worth $1,827,000 after buying an additional 694 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock worth $20,885,000 after buying an additional 454,055 shares in the last quarter.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.